Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia. [PDF]
Int J Mol Sci, 2021 Dyslipidemia is characterized by increasing plasma levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TGs) and TG-rich lipoproteins (TGRLs) and is a major risk factor for the development of atherosclerotic cardiovascular disorders (ASCVDs).
Chen PY +5 more
europepmc +5 more sources
Angiopoietin-like Protein 3 (ANGPTL3) Targeting in the Management of Dyslipidemias. [PDF]
Int J Mol SciCardiovascular disease (CVD) remains the leading cause of morbidity and mortality, despite advances in pharmacological prevention and treatment. The burden of CVD necessitates implementing the treatment of risk factors including dyslipidemia. Pharmaceutical advancements and in depth understanding of pathophysiology have enabled innovative therapies ...
Kosmas CE +4 more
europepmc +3 more sources
Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities. [PDF]
J Biol Chem, 2021 Elevated plasma triglycerides are a risk factor for coronary artery disease, which is the leading cause of death worldwide. Lipoprotein lipase (LPL) reduces triglycerides in the blood by hydrolyzing them from triglyceride-rich lipoproteins to release free fatty acids.
Gunn KH +5 more
europepmc +4 more sources
Heliyon, 2023 High metastatic potential and resistance to immunotherapy lead to poor survival in patients with ovarian cancer. Angiopoietin-like protein 3 is aberrantly expressed and exerts diverse roles in the progression of several cancers.
Yuxian Wu, Yaqun Zheng, Zhijun Jin
doaj +1 more source
Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk. [PDF]
Eur Heart JAbstract Background and Aims RNA-based, antibody-based, and genome editing-based therapies are currently under investigation to determine if the inhibition of angiopoietin-like protein-3 (ANGPTL3) could reduce lipoprotein-lipid levels and atherosclerotic cardiovascular disease (ASCVD) risk.
Gobeil É +16 more
europepmc +3 more sources
Regulation of Angiopoietin-Like Proteins (ANGPTLs) 3 and 8 by Insulin [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2015 Circulating ANGPTL8 has recently been used as a marker of insulin action. We studied expression and insulin regulation of ANGPTL8 and ANGPTL3 in vivo and in vitro.Expression of ANGPTL8 and ANGPTL3 was studied in 34 paired samples of human liver and adipose tissue.
Haridas, P. A. Nidhina +16 more
openaire +3 more sources
Correction to: Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. [PDF]
Circulation, 2021 europepmc +4 more sources
Angiopoietin-Like Protein 3 Expression is Down-Regulated in Experimentally Pregnant Toxemic Goats
Journal of Integrative Agriculture, 2012 Pregnancy toxemia is a metabolic disorder of lipid and glucose. Recent investigations have found that angiopoietin-like protein 3 (ANGPTL3) can contribute to disorder of carbohydrate and lipid metabolism.
Xiao-jun CHEN +9 more
doaj +1 more source
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Journal of Lipid and Atherosclerosis, 2023 Low-density lipoprotein cholesterol (LDL-C)-lowering therapy that increases LDL receptor expression in several ways robustly reduces the risk of atherosclerotic cardiovascular disease (CVD).
Ji Yoon Kim, Nam Hoon Kim
doaj +1 more source
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia. [PDF]
Circulation, 2019 Background: Hypertriglyceridemia is associated with increased cardiovascular risk and may be caused by impaired lipoprotein clearance. Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein lipase activity, increasing triglycerides and other lipids.
Ahmad Z +10 more
europepmc +3 more sources